X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUVEN LIFESCIENCES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUVEN LIFESCIENCES NOVARTIS/
SUVEN LIFESCIENCES
 
P/E (TTM) x 435.8 19.3 2,258.8% View Chart
P/BV x 30.8 3.8 815.1% View Chart
Dividend Yield % 1.5 0.6 245.7%  

Financials

 NOVARTIS   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SUVEN LIFESCIENCES
Mar-18
NOVARTIS/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs758251 302.2%   
Low Rs579155 373.5%   
Sales per share (Unadj.) Rs228.449.1 464.9%  
Earnings per share (Unadj.) Rs31.79.7 326.6%  
Cash flow per share (Unadj.) Rs32.811.4 287.6%  
Dividends per share (Unadj.) Rs10.001.50 666.7%  
Dividend yield (eoy) %1.50.7 202.3%  
Book value per share (Unadj.) Rs297.160.3 492.8%  
Shares outstanding (eoy) m24.69127.28 19.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.1 70.9%   
Avg P/E ratio x21.120.9 100.9%  
P/CF ratio (eoy) x20.417.8 114.6%  
Price / Book Value ratio x2.23.4 66.9%  
Dividend payout %31.515.4 204.1%   
Avg Mkt Cap Rs m16,50525,825 63.9%   
No. of employees `0000.71.1 62.3%   
Total wages/salary Rs m1,445613 235.9%   
Avg. sales/employee Rs Th8,441.35,832.6 144.7%   
Avg. wages/employee Rs Th2,163.6571.5 378.6%   
Avg. net profit/employee Rs Th1,173.11,153.8 101.7%   
INCOME DATA
Net Sales Rs m5,6396,253 90.2%  
Other income Rs m1,718233 738.4%   
Total revenues Rs m7,3576,485 113.4%   
Gross profit Rs m-631,982 -3.2%  
Depreciation Rs m25213 11.9%   
Interest Rs m5546 119.4%   
Profit before tax Rs m1,5751,955 80.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792718 110.2%   
Profit after tax Rs m7841,237 63.4%  
Gross profit margin %-1.131.7 -3.5%  
Effective tax rate %50.336.7 136.8%   
Net profit margin %13.919.8 70.3%  
BALANCE SHEET DATA
Current assets Rs m9,5225,622 169.4%   
Current liabilities Rs m3,2961,168 282.3%   
Net working cap to sales %110.471.2 155.0%  
Current ratio x2.94.8 60.0%  
Inventory Days Days3781 45.0%  
Debtors Days Days2836 79.1%  
Net fixed assets Rs m463,325 1.4%   
Share capital Rs m123127 96.9%   
"Free" reserves Rs m7,2137,547 95.6%   
Net worth Rs m7,3367,674 95.6%   
Long term debt Rs m014 0.0%   
Total assets Rs m11,1059,135 121.6%  
Interest coverage x29.543.2 68.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 74.2%   
Return on assets %7.614.0 53.8%  
Return on equity %10.716.1 66.3%  
Return on capital %22.226.0 85.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m615,066 1.2%   
Fx outflow Rs m3,6302,001 181.4%   
Net fx Rs m-3,5703,065 -116.5%   
CASH FLOW
From Operations Rs m1,610699 230.2%  
From Investments Rs m687-6 -11,262.3%  
From Financial Activity Rs m-2,677-577 463.9%  
Net Cashflow Rs m-380116 -326.4%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.0 -  
FIIs % 1.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 36.5 58.9%  
Shareholders   41,647 37,287 111.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; Metal & Automobile Stocks Slip(12:30 pm)

Share markets in India are presently trading on a negative note. Barring finance sector, all sectoral indices are trading in red with stocks in the metal sector.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2019 02:53 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS